O	0	4	Open
O	4	5	-
O	5	10	label
O	11	21	randomized
O	22	30	clinical
O	31	36	trial
O	37	39	of
O	40	48	standard
B-intervention	49	60	neoadjuvant
I-intervention	61	73	chemotherapy
I-intervention	74	78	with
I-intervention	79	89	paclitaxel
I-intervention	90	98	followed
I-intervention	99	101	by
I-intervention	102	105	FEC
O	106	112	versus
O	113	116	the
B-control	117	128	combination
I-control	129	131	of
I-control	132	142	paclitaxel
I-control	143	146	and
I-control	147	157	everolimus
I-control	158	166	followed
I-control	167	169	by
I-control	170	173	FEC
O	174	176	in
O	177	182	women
O	183	187	with
O	188	194	triple
O	195	203	receptor
O	203	204	-
O	204	212	negative
O	213	219	breast
O	220	226	cancer
O	226	227	â€ 
O	227	228	.

O	229	239	Everolimus
O	240	255	synergistically
O	256	264	enhances
O	265	271	taxane
O	271	272	-
O	272	279	induced
O	280	292	cytotoxicity
O	293	295	in
O	296	302	breast
O	303	309	cancer
O	310	315	cells
O	316	318	in
O	319	324	vitro
O	325	328	and
O	329	331	in
O	332	336	vivo
O	337	339	in
O	340	348	addition
O	349	351	to
O	352	365	demonstrating
O	366	367	a
O	368	374	direct
O	375	392	antiproliferative
O	393	401	activity
O	401	402	.

O	403	405	We
O	406	409	aim
O	410	412	to
O	413	422	determine
O	423	439	pharmacodynamics
O	440	447	changes
O	448	451	and
O	452	460	response
O	461	463	of
O	464	470	adding
O	471	481	everolimus
O	482	484	to
O	485	493	standard
O	494	505	neoadjuvant
O	506	518	chemotherapy
O	519	521	in
O	522	528	triple
O	528	529	-
O	529	537	negative
O	538	544	breast
O	545	551	cancer
O	552	553	(
O	553	557	TNBC
O	557	558	)
O	558	559	.

O	560	565	Phase
O	566	568	II
O	569	574	study
O	575	577	in
B-eligibility	578	586	patients
I-eligibility	587	591	with
I-eligibility	592	599	primary
I-eligibility	600	604	TNBC
O	605	615	randomized
O	616	618	to
O	619	620	T
O	620	621	-
O	621	624	FEC
O	625	626	(
O	626	636	paclitaxel
O	637	639	80
O	640	642	mg
O	642	643	/
O	643	644	m
O	644	645	(
O	645	646	2
O	646	647	)
O	648	649	i
O	649	650	.
O	650	651	v
O	651	652	.
O	653	659	weekly
O	660	663	for
O	664	666	12
O	667	672	weeks
O	672	673	,
O	674	682	followed
O	683	685	by
O	686	687	5
O	687	688	-
O	688	700	fluorouracil
O	701	704	500
O	705	707	mg
O	707	708	/
O	708	709	m
O	709	710	(
O	710	711	2
O	711	712	)
O	712	713	,
O	714	724	epirubicin
O	725	728	100
O	729	731	mg
O	731	732	/
O	732	733	m
O	733	734	(
O	734	735	2
O	735	736	)
O	736	737	,
O	738	741	and
O	742	758	cyclophosphamide
O	759	762	500
O	763	765	mg
O	765	766	/
O	766	767	m
O	767	768	(
O	768	769	2
O	769	770	)
O	771	776	every
O	777	778	3
O	779	784	weeks
O	785	788	for
O	789	793	four
O	794	800	cycles
O	800	801	)
O	802	808	versus
O	809	811	TR
O	811	812	-
O	812	815	FEC
O	816	817	(
O	817	827	paclitaxel
O	828	830	80
O	831	833	mg
O	833	834	/
O	834	835	m
O	835	836	(
O	836	837	2
O	837	838	)
O	839	840	i
O	840	841	.
O	841	842	v
O	842	843	.
O	844	847	and
O	848	858	everolimus
O	859	861	30
O	862	864	mg
O	865	867	PO
O	868	874	weekly
O	875	878	for
O	879	881	12
O	882	887	weeks
O	887	888	,
O	889	897	followed
O	898	900	by
O	901	904	FEC
O	904	905	)
O	905	906	.

O	907	912	Tumor
O	913	920	samples
O	921	925	were
O	926	935	collected
O	936	938	to
O	939	945	assess
O	946	955	molecular
O	956	963	changes
O	964	966	in
O	967	970	the
O	971	975	PI3K
O	975	976	/
O	976	979	AKT
O	979	980	/
O	980	984	mTOR
O	985	992	pathway
O	992	993	,
O	994	996	at
O	997	1005	baseline
O	1005	1006	,
O	1007	1009	48
O	1010	1011	h
O	1011	1012	,
O	1013	1015	12
O	1016	1021	weeks
O	1021	1022	,
O	1023	1026	and
O	1027	1029	at
O	1030	1037	surgery
O	1038	1040	by
O	1041	1048	reverse
O	1049	1054	phase
O	1055	1062	protein
O	1063	1069	arrays
O	1070	1071	(
O	1071	1075	RPPA
O	1075	1076	)
O	1076	1077	.

O	1078	1086	Clinical
O	1087	1090	end
O	1091	1097	points
O	1098	1106	included
B-outcome-Measure	1107	1109	12
I-outcome-Measure	1109	1110	-
I-outcome-Measure	1110	1114	week
I-outcome-Measure	1115	1123	clinical
I-outcome-Measure	1124	1132	response
I-outcome-Measure	1133	1137	rate
I-outcome-Measure	1138	1139	(
I-outcome-Measure	1139	1141	12
I-outcome-Measure	1141	1142	-
I-outcome-Measure	1142	1146	week
I-outcome-Measure	1147	1149	RR
I-outcome-Measure	1149	1150	)
O	1150	1151	,
B-outcome-Measure	1152	1164	pathological
I-outcome-Measure	1165	1173	complete
I-outcome-Measure	1174	1182	response
I-outcome-Measure	1183	1184	(
I-outcome-Measure	1184	1187	pCR
I-outcome-Measure	1187	1188	)
O	1188	1189	,
O	1190	1193	and
B-outcome-Measure	1194	1202	toxicity
O	1202	1203	.

B-total-participants	1204	1209	Sixty
I-total-participants	1209	1210	-
I-total-participants	1210	1213	two
O	1214	1222	patients
O	1223	1227	were
O	1228	1238	registered
O	1238	1239	,
O	1240	1243	and
B-total-participants	1244	1246	50
O	1247	1251	were
O	1252	1262	randomized
O	1262	1263	,
B-intervention-participants	1264	1266	27
O	1267	1275	received
O	1276	1277	T
O	1277	1278	-
O	1278	1281	FEC
O	1281	1282	,
O	1283	1286	and
B-control-participants	1287	1289	23
O	1290	1298	received
B-control	1299	1301	TR
I-control	1301	1302	-
I-control	1302	1305	FEC
O	1305	1306	.

O	1307	1313	Median
O	1314	1317	age
O	1318	1321	was
B-age	1322	1324	48
I-age	1325	1326	(
I-age	1326	1331	range
I-age	1332	1334	31
I-age	1334	1335	-
I-age	1335	1337	75
I-age	1337	1338	)
O	1338	1339	.

O	1340	1345	There
O	1346	1349	was
O	1350	1364	downregulation
O	1365	1367	of
O	1368	1371	the
O	1372	1376	mTOR
O	1377	1384	pathway
O	1385	1387	at
O	1388	1390	48
O	1391	1392	h
O	1393	1395	in
O	1396	1399	the
O	1400	1402	TR
O	1402	1403	-
O	1403	1406	FEC
O	1407	1410	arm
O	1410	1411	.

B-outcome	1412	1418	Twelve
I-outcome	1418	1419	-
I-outcome	1419	1423	week
I-outcome	1424	1426	RR
O	1427	1429	by
O	1430	1440	ultrasound
O	1441	1445	were
B-iv-bin-percent	1446	1448	29
I-iv-bin-percent	1448	1449	.
I-iv-bin-percent	1449	1450	6
I-iv-bin-percent	1450	1451	%
O	1452	1458	versus
B-cv-bin-percent	1459	1461	47
I-cv-bin-percent	1461	1462	.
I-cv-bin-percent	1462	1463	8
I-cv-bin-percent	1463	1464	%
O	1464	1465	,
O	1466	1467	(
O	1467	1468	P
O	1469	1470	=
O	1471	1472	0
O	1472	1473	.
O	1473	1476	075
O	1476	1477	)
O	1477	1478	,
O	1479	1482	and
B-outcome	1483	1486	pCR
O	1487	1491	were
B-iv-bin-percent	1492	1494	25
I-iv-bin-percent	1494	1495	.
I-iv-bin-percent	1495	1496	9
I-iv-bin-percent	1496	1497	%
O	1498	1504	versus
B-cv-bin-percent	1505	1507	30
I-cv-bin-percent	1507	1508	.
I-cv-bin-percent	1508	1509	4
I-cv-bin-percent	1509	1510	%
O	1511	1512	(
O	1512	1513	P
O	1514	1515	=
O	1516	1517	0
O	1517	1518	.
O	1518	1520	76
O	1520	1521	)
O	1522	1525	for
O	1526	1527	T
O	1527	1528	-
O	1528	1531	FEC
O	1532	1535	and
O	1536	1538	TR
O	1538	1539	-
O	1539	1542	FEC
O	1542	1543	,
O	1544	1556	respectively
O	1556	1557	.

O	1558	1562	mTOR
O	1563	1577	downregulation
O	1578	1580	at
O	1581	1583	48
O	1584	1585	h
O	1586	1589	did
O	1590	1593	not
O	1594	1603	correlate
O	1604	1608	with
B-outcome	1609	1611	12
I-outcome	1611	1612	-
I-outcome	1612	1616	week
I-outcome	1617	1619	RR
O	1620	1622	in
O	1623	1626	the
O	1627	1629	TR
O	1629	1630	-
O	1630	1633	FEC
O	1634	1639	group
O	1640	1641	(
O	1641	1642	P
O	1643	1644	=
O	1645	1646	0
O	1646	1647	.
O	1647	1649	58
O	1649	1650	)
O	1650	1651	.

O	1652	1656	Main
O	1657	1660	NCI
O	1661	1666	grade
O	1667	1668	3
O	1668	1669	/
O	1669	1670	4
O	1671	1681	toxicities
O	1682	1690	included
B-outcome	1691	1697	anemia
O	1697	1698	,
B-outcome	1699	1710	neutropenia
O	1710	1711	,
B-outcome	1712	1716	rash
I-outcome	1716	1717	/
I-outcome	1717	1729	desquamation
O	1729	1730	,
O	1731	1734	and
B-outcome	1735	1743	vomiting
O	1744	1746	in
O	1747	1751	both
O	1752	1756	arms
O	1756	1757	.

O	1758	1763	There
O	1764	1767	was
B-cv-bin-abs	1768	1771	one
O	1772	1776	case
O	1777	1779	of
B-outcome	1780	1785	grade
I-outcome	1786	1787	3
I-outcome	1788	1799	pneumonitis
O	1800	1802	in
O	1803	1806	the
O	1807	1809	TR
O	1809	1810	-
O	1810	1813	FEC
O	1814	1817	arm
O	1817	1818	.

B-outcome	1819	1821	No
I-outcome	1822	1827	grade
I-outcome	1828	1829	3
I-outcome	1829	1830	/
I-outcome	1830	1831	4
I-outcome	1832	1842	stomatitis
O	1843	1851	occurred
O	1851	1852	.

O	1853	1856	The
O	1857	1865	addition
O	1866	1868	of
O	1869	1879	everolimus
O	1880	1882	to
O	1883	1893	paclitaxel
O	1894	1897	was
B-outcome	1898	1902	well
I-outcome	1903	1912	tolerated
O	1912	1913	.

O	1914	1924	Everolimus
O	1925	1938	downregulated
O	1939	1943	mTOR
O	1944	1953	signaling
O	1954	1957	but
O	1958	1972	downregulation
O	1973	1975	of
O	1976	1980	mTOR
O	1981	1983	at
O	1984	1986	48
O	1987	1988	h
O	1989	1992	did
O	1993	1996	not
O	1997	2006	correlate
O	2007	2011	with
O	2012	2014	12
O	2014	2015	-
O	2015	2019	week
O	2020	2022	RR
O	2023	2025	in
O	2026	2029	the
O	2030	2032	TR
O	2032	2033	-
O	2033	2036	FEC
O	2037	2042	group
O	2042	2043	.

O	2044	2055	NCT00499603
O	2055	2056	.
